Glenmark Pharmaceuticals Limited has informed the Exchange about General Updates - US FDA Communication
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has received a warning letter from the U.S. FDA for its manufacturing facility in Indore, Madhya Pradesh, following an inspection conducted from February 3 to February 14, 2025. This is a follow-up to an earlier communication from May 9, 2025, when the facility was classified as OAI (Official Action Indicated) by the U.S. FDA. The company has stated that the warning letter will not disrupt supplies or affect existing revenues from this facility, and that no data integrity issues were flagged. Glenmark has committed to working with the U.S. FDA to resolve the concerns at the earliest while maintaining cGMP quality standards across all its plants.
The warning letter is a negative regulatory signal but is partially cushioned by the company's assurance of no supply disruption or revenue impact. Short-term stock sentiment may be negative due to regulatory overhang, though the absence of data integrity concerns limits the severity. Investors should watch for updates on remediation progress and any future FDA actions.